JP2024528066A5 - - Google Patents
Info
- Publication number
- JP2024528066A5 JP2024528066A5 JP2024505314A JP2024505314A JP2024528066A5 JP 2024528066 A5 JP2024528066 A5 JP 2024528066A5 JP 2024505314 A JP2024505314 A JP 2024505314A JP 2024505314 A JP2024505314 A JP 2024505314A JP 2024528066 A5 JP2024528066 A5 JP 2024528066A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- triazole
- phenol
- pyridazin
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203761P | 2021-07-30 | 2021-07-30 | |
| US63/203,761 | 2021-07-30 | ||
| PCT/US2022/038870 WO2023009816A1 (en) | 2021-07-30 | 2022-07-29 | Heteroaryl compounds for treating huntington's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528066A JP2024528066A (ja) | 2024-07-26 |
| JP2024528066A5 true JP2024528066A5 (cg-RX-API-DMAC10.html) | 2025-07-31 |
Family
ID=83149486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505314A Pending JP2024528066A (ja) | 2021-07-30 | 2022-07-29 | ハンチントン病を処置するためのヘテロアリール化合物 |
Country Status (16)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| CA3249778A1 (en) * | 2022-06-15 | 2023-12-21 | Ptc Therapeutics, Inc. | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) * | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| JP2022525417A (ja) * | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
-
2022
- 2022-07-29 CN CN202280066651.3A patent/CN118159539A/zh active Pending
- 2022-07-29 MX MX2024001417A patent/MX2024001417A/es unknown
- 2022-07-29 PE PE2024000170A patent/PE20240929A1/es unknown
- 2022-07-29 KR KR1020247003414A patent/KR20240054264A/ko active Pending
- 2022-07-29 IL IL310440A patent/IL310440A/en unknown
- 2022-07-29 JP JP2024505314A patent/JP2024528066A/ja active Pending
- 2022-07-29 CA CA3227287A patent/CA3227287A1/en active Pending
- 2022-07-29 CR CR20240043A patent/CR20240043A/es unknown
- 2022-07-29 EP EP22761694.3A patent/EP4377317A1/en active Pending
- 2022-07-29 WO PCT/US2022/038870 patent/WO2023009816A1/en not_active Ceased
- 2022-07-29 AU AU2022320725A patent/AU2022320725A1/en active Pending
- 2022-07-29 AR ARP220102027A patent/AR126612A1/es unknown
- 2022-07-29 US US18/293,349 patent/US20240336613A1/en active Pending
- 2022-08-01 TW TW111128808A patent/TW202321247A/zh unknown
-
2024
- 2024-01-29 CL CL2024000250A patent/CL2024000250A1/es unknown
- 2024-01-30 CO CONC2024/0000890A patent/CO2024000890A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10899761B2 (en) | Heterocyclic compounds and uses thereof | |
| JP2022153502A (ja) | 関節疾患及び皮膚疾患の治療のためのラパマイシンとメトホルミンの併用 | |
| US8507504B2 (en) | Process for producing bicycloaniline derivatives | |
| US8642602B2 (en) | Method of inhibiting fibrogenesis and treating fibrotic disease | |
| JP7641894B2 (ja) | がん治療におけるｅｎｔファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ | |
| IL310440A (en) | Heteroaryl compounds for treating huntington's disease | |
| JP2019500352A5 (cg-RX-API-DMAC10.html) | ||
| US8691777B2 (en) | Combination therapy | |
| BRPI0911273B1 (pt) | Composição farmacêutica compreendendo um inibidor de DPP-IV, bem como processo para sua preparação | |
| US20220354842A1 (en) | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents | |
| CN1128615C (zh) | 预防和治疗癌性疾病的药物组合物及其制备方法 | |
| CN112168830B (zh) | 一种含有mTOR抑制剂的药物组合及其应用 | |
| CN101065127A (zh) | 包含埃博霉素和蛋白酪氨酸激酶抑制剂的组合产品及其药物用途 | |
| CA3130244A1 (en) | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | |
| CN120284929A (zh) | 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂 | |
| JP2025000796A (ja) | がん治療におけるｅｎｔファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ | |
| WO2023040810A1 (en) | Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors | |
| KR20250151363A (ko) | 골수증식성 신생물의 치료 방법 | |
| JP2024546846A (ja) | マントル細胞リンパ腫の治療のためのアベマシクリブ並びにＰＩ３Ｋ阻害剤及び／又はｍＴＯＲ阻害剤を含む薬剤の組み合わせ | |
| TW202342032A (zh) | 含有ｍａｌｔ１抑制劑作為有效成分的癌治療劑 | |
| JP7833619B2 (ja) | 光学活性なアザビシクロ環誘導体を含むがんの治療剤 | |
| BE1026615B1 (fr) | Combinaison d’un inhibiteur du récepteur a2a et d'un agent anticancéreux | |
| WO2015016694A1 (es) | Composición sólida estable de inmunosupresores | |
| HK40034611B (en) | A pharmaceutical composition containing mtor inhibitor and use thereof | |
| HK40034611A (en) | A pharmaceutical composition containing mtor inhibitor and use thereof |